Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857961 · ClinicalTrials.gov registry record · Phase 2
A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00857961 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 21 participants.
The verdict
NCT00857961, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the product.
Interventions
- DRUG Testosterone MD-Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857961
The ClinicalTrials.gov registry entry for NCT00857961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testosterone MD-Lotion is the first listed.
NCT00857961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857961 about?
NCT00857961 is a clinical study titled "A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations". Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the p...
What is the current status of trial NCT00857961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-10. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00857961?
The interventions under investigation include: Testosterone MD-Lotion (DRUG).
Who is sponsoring clinical trial NCT00857961?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.